^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

Tumor mutation burden (TMB), PD-L1, IFN-? signaling identify subgroups of patients (pts) who benefit from durvalumab (D, anti-PDL1) or D and tremelimumab (T, anti-CTLA4) treatment in urothelial bladder cancer (UC)

Published date:
09/30/2019
Excerpt:
Study 10/NCT02261220 was a phase I trial including 190 2L UC pts treated with D (20 mg/kg Q4W) +T (1 mg/kg Q4W)...In Study 10, TMB and PD-L1 double positive pts (n = 14, 24%) had best OS and pts low in both had worst (n = 19, 32%, HR = 0.23, p = 0.01).
DOI:
10.1093/annonc/mdz253